Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Esperion Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.316 Ladies and gentlemen, thank you for standing by and welcome. 00:00:04.316 -- 00:00:08.921 At this time, all participants are in a listen-only mode. 00:00:08.921 -- 00:00:13.747 Following the presentation, there will be a question and answer session. 00:00:13.747 -- 00:00:17.411 Please be advised that today's conference call may be recorded. 00:00:17.411 -- 00:00:23.278 I would now like to turn the call over to Alina Venezia, Director 00:00:23.278 -- 00:00:27.002 of Investor Relations for Asperian Therapeutics. 00:00:27.002 -- 00:00:29.502 You may begin. 00:00:37.122 -- 00:00:38.324 Thank you, operators. 00:00:38.324 -- 00:00:43.572 Good morning, and welcome to Experian's fourth quarter and full year 2024 earnings 00:00:43.572 -- 00:00:49.040 conference call. With us on today's call are Sheldon Koenig, President and CEO, 00:00:49.040 -- 00:00:54.127 and Ben Halliday, CFO. Other members of the executive team will be available for 00:00:54.127 -- 00:00:57.312 Q&A following our prepared remarks. 00:00:57.312 -- 00:01:02.705 We issued a press release earlier this morning detailing the content of today's call. 00:01:02.705 -- 00:01:06.891 A copy can be found on the investor page of our website, together with a copy of the 00:01:06.891 -- 00:01:10.216 presentation that we will also be referencing. 00:01:10.216 -- 00:01:14.562 I want to remind callers that the information discussed on the call today is covered 00:01:14.562 -- 00:01:19.850 under the safe harbor provisions of the private securities litigation reform act. 00:01:19.850 -- 00:01:24.157 I caution listeners that management will be making forward-looking statements. 00:01:24.157 -- 00:01:29.168 Actual results could differ materially from those stated or implied by our 00:01:29.168...